Vicus Capital Makes New $281,000 Investment in Becton, Dickinson and Company (NYSE:BDX)

Vicus Capital bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,067 shares of the medical instruments supplier’s stock, valued at approximately $281,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Magnolia Capital Management Ltd. purchased a new stake in Becton, Dickinson and in the fourth quarter worth $55,000. NTV Asset Management LLC lifted its holdings in Becton, Dickinson and by 11.3% during the 3rd quarter. NTV Asset Management LLC now owns 6,494 shares of the medical instruments supplier’s stock valued at $1,596,000 after buying an additional 661 shares in the last quarter. FIL Ltd boosted its position in Becton, Dickinson and by 174.6% in the 3rd quarter. FIL Ltd now owns 340,420 shares of the medical instruments supplier’s stock valued at $83,682,000 after buying an additional 216,440 shares during the period. Pinebridge Investments L.P. grew its stake in Becton, Dickinson and by 6.8% in the 3rd quarter. Pinebridge Investments L.P. now owns 42,022 shares of the medical instruments supplier’s stock worth $10,330,000 after acquiring an additional 2,676 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its position in shares of Becton, Dickinson and by 52.1% during the third quarter. Rafferty Asset Management LLC now owns 9,157 shares of the medical instruments supplier’s stock worth $2,251,000 after acquiring an additional 3,137 shares during the period. Hedge funds and other institutional investors own 86.58% of the company’s stock.

In other Becton, Dickinson and news, EVP Betty D. Larson sold 14,374 shares of the firm’s stock in a transaction on Friday, February 25th. The shares were sold at an average price of $271.90, for a total value of $3,908,290.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.50% of the company’s stock.

Shares of BDX opened at $252.20 on Tuesday. The company has a 50 day moving average of $263.02 and a two-hundred day moving average of $257.33. The company has a market cap of $71.82 billion, a price-to-earnings ratio of 39.78, a price-to-earnings-growth ratio of 3.19 and a beta of 0.64. The company has a quick ratio of 0.78, a current ratio of 1.53 and a debt-to-equity ratio of 0.72. Becton, Dickinson and Company has a twelve month low of $235.13 and a twelve month high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 EPS for the quarter, beating the consensus estimate of $2.99 by $0.19. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The firm had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. During the same quarter in the prior year, the business posted $3.19 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, sell-side analysts expect that Becton, Dickinson and Company will post 12.74 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th will be paid a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.38%. Becton, Dickinson and’s payout ratio is 54.89%.

Several research analysts recently issued reports on BDX shares. Wells Fargo & Company increased their price objective on Becton, Dickinson and from $275.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Friday, April 1st. Morgan Stanley lifted their price objective on Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a report on Monday, April 11th. Argus increased their target price on shares of Becton, Dickinson and from $275.00 to $310.00 in a report on Monday, February 28th. Piper Sandler reduced their price target on shares of Becton, Dickinson and from $265.00 to $255.00 in a report on Thursday, May 5th. Finally, StockNews.com downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday. Seven analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Becton, Dickinson and currently has a consensus rating of “Hold” and a consensus target price of $275.63.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

See Also

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.